Nuggehally R Srinivas
Overview
Explore the profile of Nuggehally R Srinivas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
264
Citations
682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kallem R, Yeager M, Chan R, Fletcher K, Neal K, Srinivas N
Biomed Chromatogr
. 2025 Feb;
39(4):e70023.
PMID: 39968937
Bexicaserin is a highly selective 5HT receptor agonist being developed for the treatment of seizures associated with developmental and epileptic encephalopathies (DEEs). We report an LC-MS/MS method for the quantitative...
2.
Kallem R, Yeager M, Chan R, Fletcher K, Neal K, Srinivas N
Biomed Chromatogr
. 2025 Jan;
39(2):e6079.
PMID: 39821227
Bexicaserin is a highly selective agonist at the 5-HT receptor in clinical development for the treatment of seizures associated with developmental and epileptic encephalopathies (DEEs). We report an LC-MS/MS method...
3.
Srinivas N, Kallem R, Bartlett M
Biomed Chromatogr
. 2024 Jul;
38(9):e5954.
PMID: 38962861
Given the inherent complexities of bioanalysis, the role of incurred sample reanalysis (ISR) is increasingly appreciated in regulatory bioanalysis. Incurred sample reanalysis has evolved as an integral part of an...
4.
Srinivas N, Bartlett M
Biomed Chromatogr
. 2024 Feb;
38(3):e5843.
PMID: 38316616
No abstract available.
5.
Kurakula M, Chen L, Tiwari A, Srinivas N, Dash R, Panizzi P, et al.
Crit Rev Ther Drug Carrier Syst
. 2021 Aug;
38(4):1-38.
PMID: 34369738
Melanoma is one of the most aggressive forms of cancer with limited treatment options available. Successful treatment involves a combination of surgical resection of the tumor; chemotherapy and immunotherapy. Given...
6.
Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection?
Dash R, Veeravalli V, Thomas J, Rosenfeld C, Mehta N, Srinivas N
Future Med Chem
. 2020 Dec;
13(2):157-171.
PMID: 33275044
In the present era of drug development, quantification of drug concentrations following pharmacokinetic studies has preferentially been performed using plasma as a matrix rather than whole blood. However, it is...
7.
Sulochana S, Trivedi R, Srinivas N, Mullangi R
Biomed Chromatogr
. 2020 Oct;
35(1):e4996.
PMID: 33047346
Immuno-oncology (IO) is an emerging option to treat cancer malignancies. In the last two years, IO has accounted for more than 90% of the new active drugs in various therapeutic...
8.
Gabani B, Dixit A, Kiran V, Bestha R, Narayanan B, Srinivas N, et al.
Xenobiotica
. 2020 Sep;
51(2):202-209.
PMID: 32930648
Lumefantrine (LFN) is a chiral antimalarial drug. Enantioselective attributes and absolute oral pharmacokinetics for (-)-LFN and (+)-LFN have been characterized in mice. No stereoselectivity was seen with either of the...
9.
Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, et al.
Pharmacol Res Perspect
. 2020 Aug;
8(4):e00565.
PMID: 32790160
Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a...
10.
Gabani B, Saini N, Jairam R, Shrinivas P, Trivedi R, Srinivas N, et al.
Biomed Chromatogr
. 2020 Jul;
34(11):e4939.
PMID: 32614997
A selective, sensitive and rapid LC-MS/MS method has been developed and validated as per US Food and Drug Administration regulatory guidelines for the simultaneous quantitation of colchicine and febuxostat in...